# US 2023/0055593 A1 · Pharmaceutical composition containing b-lapachone as active ingredient for prevention or treatment of cholestatic liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055593 A1
- Document ID: US20230055593A1
- Status: Published application
- Kind: A1
- Application number: 17/942,505
- Filed: 2022-09-12
- Published: 2023-02-23
- Earliest claimed: 2020-10-08
- Assignees: Curome Biosciences Co., Ltd.
- Applicants: Curome Biosciences Co., Ltd.
- Inventors: Joo Seog YOON; Kang Sik SEO; Jeong Su HAN; Sung Je MOON; Jung Hoon LEE; Soo Bin YOON
- Web page: https://patentgrep.com/patent/US20230055593A1

## CPC

- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition containing β-lapachone as an active ingredient for prevention or treatment of cholestatic liver disease, and can provide agents for effectively preventing and treating cholestatic liver disease.

## Claims

### Claim 1

A pharmaceutical composition for prevention or treatment of cholestatic liver disease, the pharmaceutical composition containing β-lapachone or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cholestatic liver disease is at least one selected from the group consisting of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), progressive familial intrahepatic cholestasis (PFIC), benign recurrent intrahepatic cholestasis, intrahepatic cholestasis of pregnancy (ICP), cholestasis caused by viral hepatitis, cholestasis caused by alcoholic hepatitis, drug-induced cholestasis, cholestasis during parenteral nutrition, cholestasis due to malignant tumor, post-liver transplantation cholestasis, infectious cholestasis, and Alagille syndrome (AS).

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition inhibits fibrosis and inflammation of cholangiocytes.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition improves the level of at least one blood index selected from the group consisting of AST, ALT, ALP, and bilirubin in the blood.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the inhibiting of fibrosis is inhibiting at least one selected from fibrosis factors consisting of collagen type I alpha 1 (Col1α1), collagen type IV alpha 1 (Col4α1), alpha-smooth muscle actin (α-SMA), fibronectin, transforming growth factor beta 1 (TGF-β1), collagen type I alpha 2 (Col1α2), and transforming growth factor beta 2 (TGF-β2).

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, wherein the inhibiting of inflammation is inhibiting at least one selected from inflammatory cytokine factors consisting of interleukin-1beta (IL-1β), interleukin-6 (IL-6), interleukin-18 (IL-18), interferon-γ (INF-γ), tumor necrosis factor-α (TNF-α), tumor necrosis factor-β (TNF-β), and monocyte chemoattractant protein-1 (MCP-1).

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cholestatic liver disease is accompanied by inflammatory bowel disease.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition inhibits fibrosis and inflammatory cytokines in colon tissues.

### Claim 10

A health functional food for prevention or amelioration of cholestatic liver disease, the heath functional food comprising β-lapachone or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 11 (depends on 10)

The health functional food of claim 10, wherein the cholestatic liver disease is accompanied by inflammatory bowel disease.

### Claim 12 (depends on 11)

The health functional food of claim 11, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.

### Claim 13

A method for prevention or treatment of cholestatic liver disease, comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition containing β-lapachone or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cholestatic liver disease is at least one selected from the group consisting of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), progressive familial intrahepatic cholestasis (PFIC), benign recurrent intrahepatic cholestasis, intrahepatic cholestasis of pregnancy (ICP), cholestasis caused by viral hepatitis, cholestasis caused by alcoholic hepatitis, drug-induced cholestasis, cholestasis during parenteral nutrition, cholestasis due to malignant tumor, post-liver transplantation cholestasis, infectious cholestasis, and Alagille syndrome (AS).

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition inhibits fibrosis and inflammation of cholangiocytes.

### Claim 16 (depends on 13)

The method of claim 13, wherein the composition improves the level of at least one blood index selected from the group consisting of AST, ALT, ALP, and bilirubin in the blood.

### Claim 17 (depends on 15)

The method of claim 15, wherein the inhibiting of fibrosis comprises inhibiting at least one selected from fibrosis factors consisting of collagen type I alpha 1 (Col1α1), collagen type IV alpha 1 (Col4α1), alpha-smooth muscle actin (α-SMA), fibronectin, transforming growth factor beta 1 (TGF-β1), collagen type I alpha 2 (Col1α2), and transforming growth factor beta 2 (TGF-β2).

### Claim 18

The method of claim of 15, wherein the inhibiting of inflammation comprises inhibiting at least one selected from inflammatory cytokine factors consisting of interleukin-1beta (IL-1β), interleukin-6 (IL-6), interleukin-18 (IL-18), interferon-γ (INF-γ), tumor necrosis factor-α (TNF-α), tumor necrosis factor-β (TNF-β), and monocyte chemoattractant protein-1 (MCP-1).

### Claim 19 (depends on 13)

The method of claim 13, wherein the cholestatic liver disease is accompanied by inflammatory bowel disease.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
